21 July 2020 

AstraZeneca has reported positive data from the Phase I/II COV001 clinical trial of Covid-19 vaccine, AZD1222, which is being developed by the University of Oxford . Early data showed that the vaccine candidate was tolerated and generated strong immune responses in all evaluated participants. Findings have been published in The Lancet journal.

UK-based Synairgen has reported positive clinical data of its inhaled interferon beta candidate, SNG001, for the treatment of patients hospitalised with Covid-19. The therapeutic was found to reduce the risk of developing severe disease by 79%, when compared to placebo. Synairgen added that patients on SNG001 were more than twice as likely to recover.

Pfizer and BioNTech have announced that their Covid-19 vaccine candidate, BNT162b1, produced dose-dependent SARS-CoV-2-neutralising titers following the second dose in a Phase I/II clinical trial being performed in Germany. The company added that the product for the first time demonstrated a concurrent induction of CD4+ and CD8+ T cell responses against the virus’ receptor binding domain (RBD).

Japanese pharmaceutical firm Shionogi has plans to increase manufacturing capacity to produce enough doses of its Covid-19 vaccine for 30 million people each year by the end of 2021, according to Reuters. The aim is to triple the domestic production capacity.

In a mid-stage clinical trial, CanSino Biologics’ Covid-19 vaccine candidate Ad5-nCOV has shown positive safety profile and stimulated immune responses in the majority of participants. The vaccine was tested in a total of 508 subjects and demonstrated ability to induce both antibody and T-cell immune responses, without any serious side effects.